Thanks for posting..... FY18 is going to be an exciting for ATM.
· New Stage 4 IF just launched; benefits yet to come. (Stage 4 could provide insurance as it apparently allows A2 to maintain supply of IF to China - if CFDA is not issued.)
· Production of IF to double from October 2017. Higher margins! Fresh milk used to outsell IF. Now it is the other way around.
· New A2 brand and market extensions; eg fresh A2 milk launched in Singapore etc.
· CFDA - Key China Certification pending; high probability of success…but SP will drop if not granted.
· Lion Court Case; Likely to be won or settled in ATM’s Favour. Likely that the cost of litigation will be recovered plus possible compensation boost. Again possible downside if A2 fails.
· Health and IP Benefits; Growing research and acceptance world wide. New Research in NZ and Aus looks impressive. Increased spending on Patent protection. Busy digging that moat.
· Special Dividend; TBA, a move to dividends in FY18.
· Share buy-back; increases SP and balance sheet strength
· Investment in Synlait; has already seen impressive appreciation. More to come.
· Double digit sales growth potential; USA, UK, Europe, Singapore with Triple digit potential in China